What is the oncologic risk of stem cell treatment for heart disease?
- PMID: 21617132
- PMCID: PMC3390911
- DOI: 10.1161/CIRCRESAHA.111.246611
What is the oncologic risk of stem cell treatment for heart disease?
Comment on
-
Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy.Circ Res. 2011 May 27;108(11):1340-7. doi: 10.1161/CIRCRESAHA.110.239848. Epub 2011 Apr 14. Circ Res. 2011. PMID: 21493893 Free PMC article.
References
-
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147. - PubMed
-
- Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, Pattany PM, Zambrano JP, Hu Q, McNiece I, Heldman AW, Hare JM. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009;106:14022–14027. - PMC - PubMed
-
- Barallobre-Barreiro J, de Ilarduya OM, Moscoso I, Calvino-Santos R, Aldama G, Centeno A, Lopez-Pelaez E, Domenech N. Gene expression profiles following intracoronary injection of mesenchymal stromal cells using a porcine model of chronic myocardial infarction. Cytotherapy. 2011;13:407–418. - PubMed
-
- Bhakta S, Greco NJ, Finney MR, Scheid PE, Hoffman RD, Joseph ME, Banks JJ, Laughlin MJ, Pompili VJ. The safety of autologous intracoronary stem cell injections in a porcine model of chronic myocardial ischemia. J Invasive Cardiol. 2006;18:212–218. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical